PUBLISHER: Grand View Research | PRODUCT CODE: 2132511
PUBLISHER: Grand View Research | PRODUCT CODE: 2132511
The global psychedelic drugs market size was valued at USD 4.1 billion in 2025 and is projected to grow from USD 4.7 billion in 2026 to USD 11.7 billion by 2033, at a CAGR of 14.1% from 2026 to 2033. North America dominated the market, accounting for revenue share of 41.2% in 2025. The market is an emerging pharmaceutical market focused on the development of psychedelic compounds for the treatment of mental health and substance use disorders.
Key substances under clinical investigation include psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), N,N-dimethyltryptamine (DMT), and ibogaine. Research is primarily focused on treatment-resistant depression, major depressive disorder, post-traumatic stress disorder, and alcohol use disorder. The market is supported by ongoing clinical trials, investments by biotechnology and pharmaceutical companies, and research into treatment options for patients with inadequate response to existing therapies. However, most psychedelic drugs remain in clinical development, limiting their current commercial availability. Development also involves controlled-substance regulations, specialized administration protocols, patient monitoring, and psychological support. These requirements can increase development and treatment costs and may affect the adoption of psychedelic-based therapies. Limited long-term safety data, regulatory uncertainty, and the need for trained healthcare professionals remain key factors affecting market development.
Global Psychedelic Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psychedelic drugs market report based on drug type, indication, route of administration, distribution channel, and region: